IMV Inc IMVIQ

IMV potential to show OS in existing trials.

[QM45]

There has been a lot of speculation regarding the results of the trials IMV is conducting in light of the recent price action.

What is being missed is how significant the EXISTING resuls are in light of PROVEN and REPORTED science accumulated over last  decade.

IMV DPX Survivac is a UNIQUE delivery system of a proven MERCK vaccine our company licenced 8 years ago. IMV had it's own vaccine, but went with a superior formulation from Merck. 

This vaccine was tested in Phase 1 study by Merck with 49 patients and had shown  vaccine activated T-Cell responses in 63% of the patients. The best tumor response was SD (stable desease) in 28% of the patients. 

Few years earlier in  2012 a phase II survivin vaccine  was tested in 61 patients in melanoma. (link below:)

The study found that Survivin-specific T-Cell reactivities strongly correlate with tumor response and PATIENT SURVIVAL.

Patients vaccinated in the study that showed SURVIVIN SPECIFIC T-CELL Reactivity had a median OS of 19.6 months vs 8.6 months for the group that did not show survivin reactivity. 

That is DOUBLING of Overall Survival.

In that study of 61 patients they had one CR, 3 PR(5.5%) and 7 SD. (12.7%)

Those results despite being much weaker than what has been reported by IMV in terms of ORR,  show doubling survival benefit  in population with  Survivin specific T-Cells. 

IMV's  DPX Survivac is unique for generating  strong and sustained Survivin specific T-Cell response. It's what seperates it from standard  vaccines. 

It will be only a matter of time for existing trials to bear out not only tumor shrinkage, but also REAL SURVIVAL BENEFIT based on the above.

Seeing high percentage of  SD in our patient population as per INCYTE trial and strong Survivin specific tumor T-Cell infiltration  should corelate with patient survival as per above 61 patient study which is the ultimate high bar in terminal patients.

It's also what gets drugs approved by FDA. 




https://link.springer.com/article/10.1007%2Fs00262-012-1266-9#Sec10